Bladder Cancer
@BladderCa
Followers
2K
Following
68
Media
29
Statuses
4K
Information on Bladder Cancer
USA
Joined January 2012
Cytotoxic CD4+ T Cells in Bladder Cancer-A New License to Kill. #BladderCancer #UroToday
https://t.co/ywJeBBjtso
0
1
3
Upregulation of lncRNA plasmacytoma variant translocation 1 predicts poor prognosis in patients with muscle-invasive bladder cancer. #BladderCancer #UroToday
https://t.co/uEHkH4bwLE
0
0
2
Bladder Cancer in Times of COVID-19 in India - Pradeep P. Rao #BladderCancer #UroToday
https://t.co/TMwS5YbTJn
0
0
1
TIM-3 and TIGIT are possible immune checkpoint targets in patients with bladder cancer. #BladderCancer #UroToday
https://t.co/iel79GFaYi
0
0
3
Intraoperative upper urinary tract cytology examination is a risk factor of upper urinary tract recurrence in patients with non-muscle-invasive bladder cancer. #BladderCancer #UroToday
https://t.co/oqxiiqstBp
0
0
0
Determinants of neoadjuvant chemotherapy use in muscle-invasive bladder cancer. #BladderCancer #UroToday
https://t.co/DwSYKLJEly
0
0
0
UGN-101 (mitomycin gel): a novel treatment for low-grade upper tract urothelial carcinoma. #BladderCancer #UroToday
https://t.co/8MEt30IIt9
0
0
3
EAU 2020: Five Things I Wish I Would Have Known Earlier in My Career: Lessons from the Mentors - Bladder Cancer #BladderCancer #UroToday
https://t.co/hQjzV1FSNw
0
0
0
Associations Between Female Sex and Treatment Patterns and Outcomes for Muscle-invasive Bladder Cancer. #BladderCancer #UroToday
https://t.co/IMKBo0jDjc
0
0
0
Bladder cancer incidence rates and trends in young adults aged 20-39 years. #BladderCancer #UroToday
https://t.co/3PV9LisQTa
0
0
1
The Cancer of the Bladder Risk Assessment (COBRA) score for Estimating Cancer-Specific Survival after Radical Cystectomy: External Validation in a Large Bi-institutional Cohort. #BladderCancer #UroToday
https://t.co/O35kfiD6El
0
0
1
Can we treat bladder cancer with intravesical Bacillus Calmette-Guerin in patients with prior tuberculosis infection? A population-based cohort study. #UroToday #BladderCancer
https://t.co/VbLv8W5v7Y
0
0
0
0
0
0
Urobiome in Gender-Related Diversities of Bladder Cancer. #BladderCancer #UroToday
https://t.co/bQsomX3MR0
0
0
1
Final Overall Survival Analysis of the SOGUG Phase 2 MAJA Study: Maintenance Vinflunine Versus Best Supportive Care After First-Line Chemotherapy in Advanced Urothelial Carcinoma. #BladderCancer #UroToday
https://t.co/D78upAC4cO
0
0
1
The emerging role of antibody-drug conjugates in urothelial carcinoma. #BladderCancer #UroToday
https://t.co/g0C9XKnyjZ
0
0
0
FDA Approves Avelumab as First-Line Maintenance Treatment for Patients with Locally Advanced or Metastatic Urothelial Carcinoma #BladderCancer #UroToday
https://t.co/HII2oRPAb0
0
0
2
The RESECT Study: Improving Quality in TURBT Surgery - Veeru Kasivisvanathan #BladderCancer #UroToday
https://t.co/n3TmoJZDAP
0
0
0
FDA approves Pfizer/Merck KGaA’s Bavencio in first line bladder cancer #BladderCancer
https://t.co/tyXcF0zNxz
pharmaphorum.com
The FDA has approved Pfizer and Merck KGaA’s immunotherapy Bavencio (avelumab) as a first line maintenance therapy in bladder cancer, setting up a rivalry with alternatives from Roche and AstraZene...
0
0
2
AUA Guidelines Case-Based Panel Discussion: Bladder Cancer (Non-muscle and Muscle Invasive) - Joshua Meeks and Sima Porten #BladderCancer #UroToday
https://t.co/gKHGihwTN2
0
0
1